Oculis Holding AG (OCS) Gains from Investment Securities (2023 - 2026)
Oculis Holding AG (OCS) recorded quarterly Gains from Investment Securities of -$8939.0 in Q1 2026, down 223.34% quarter-over-quarter from $7247.3 in Q2 2025, and up 42.59% on a YoY basis from -$6268.9 in Q1 2025.
Oculis Holding AG (OCS) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Oculis Holding AG's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$8939.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 42.59% year-over-year to -$8939.0; the TTM figure through Mar 2026 stood at -$149679.7 (up 15.56% YoY), while the FY2024 annual figure was -$173511.3, down 52.39% from the prior year.
- Gains from Investment Securities was -$8939.0 for Q1 2026 at Oculis Holding AG, down from $7247.3 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $65386.6 in Q4 2023 to a low of -$213537.7 in Q2 2023.
- Historically, Gains from Investment Securities has averaged -$27429.1 across 4 years, with a median of -$11456.8 in 2024.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities sank 302.51% in 2024, then soared 143.69% in 2025.
- A 4-year view of Gains from Investment Securities shows it stood at $65386.6 in 2023, then tumbled by 302.51% to -$132416.5 in 2024, then surged by 105.47% to $7247.3 in 2025, then slumped by 223.34% to -$8939.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$8939.0 (Q1 2026), $7247.3 (Q2 2025), and -$15571.5 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,939.03 |
| Mar 31, 2026 | -8,939.03 |
| Jun 30, 2025 | 7,247.34 |
| Jun 30, 2025 | 7,247.34 |
| Mar 31, 2025 | -15,571.51 |
| Mar 31, 2025 | -15,571.51 |
| Dec 31, 2024 | -132,416.53 |
| Dec 31, 2024 | -132,416.53 |
| Sep 30, 2024 | -12,696.28 |
| Sep 30, 2024 | -12,696.28 |
| Jun 30, 2024 | -16,586.90 |
| Jun 30, 2024 | -16,586.90 |
| Mar 31, 2024 | -11,456.82 |
| Mar 31, 2024 | -11,456.82 |
| Dec 31, 2023 | 65,386.56 |
| Dec 31, 2023 | 65,386.56 |
| Sep 30, 2023 | 26,039.51 |
| Sep 30, 2023 | 26,039.51 |
| Jun 30, 2023 | -213,537.71 |
| Jun 30, 2023 | -213,537.71 |